Write a PREreview

Preclinical Evaluation of a Newcastle Disease Virus-Vectored Intranasal SARS-CoV-2 Vaccine

by Manolo Fernandez Díaz, Katherine Calderón, Aldo Rojas-Neyra, Vikram N. Vakharia, Ricardo Choque-Guevara, Angela Montalvan, Astrid Poma-Acevedo, Dora Rios-Matos, Andres Agurto- Arteaga, Maria de Grecia Cauti-Mendoza, Norma Perez-Martinez, Gisela Isasi-Rivas, Luis Tataje-Lavanda, Yacory Sernaque-Aguilar, Freddy Ygnacio-Aguirre, Manuel Criollo-Orozco, Edison Huaccachi-Gonzalez, Elmer Delgado-Ccancce, Doris Villanueva-Pérez, Ricardo Montesinos-Millan, Kristel Gutiérrez-Manchay, Katherine Pauyac-Antezana, Ingrid Ramirez-Ortiz, Stefany Quiñones-Garcia, Yudith Cauna-Orocollo, Katherine Vallejos-Sánchez, Angela Rios-Angulo, Dennis Núñez-Fernández, Mario I. Salguedo-Bohorquez, Julio Ticona, Manolo Fernández-Sánchez, Eliana Icochea, Luis Guevara-Sarmiento, Mirko Zimic, and COVID-19 Working Group in Perú.

Posted: April 27, 2021
Server: Research Square
DOI: 10.21203/rs.3.rs-420780/v1

Abstract

The COVID-19 pandemic has claimed the lives of millions of people. Vaccination is a critical tool for the control of transmission; however, the recent emergence of potentially vaccine-resistant variants renders it important to have a range of vaccines types. It is desirable that vaccines are safe, effective, easy to administer and store, and inexpensive to produce. Newcastle disease virus (NDV), responsible for respiratory disease in chickens, has no pathogenic homologue in humans. We developed two types of NDV-vectored candidate vaccines, and evaluated them in a SARS-CoV-2 challenge in hamsters. Vaccinations resulted in generation of neutralizing antibodies, prevented lung damage, and reduced viral load and viability. In conclusion, our NDV-based vaccine candidate performed well in a SARS-CoV-2 challenge and warrants evaluation in a Phase I human clinical trial. This candidate represents a promising tool in the fight against COVID-19.

You can write a PREreview of Preclinical Evaluation of a Newcastle Disease Virus-Vectored Intranasal SARS-CoV-2 Vaccine. A PREreview is a review of a preprint and can vary from a few sentences to a lengthy report, similar to a journal-organized peer-review report.

Before you start

We will ask you to log in with your ORCID iD. If you don’t have an iD, you can create one.